{"description":"Documents matching 'pandemic compliance'","count":3501,"total_pages":50,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=pandemic+compliance&format=json&page=2","results":[{"title":"Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments","type":"Proposed Rule","abstract":"The Food and Drug Administration (FDA, the Agency, or we) is proposing to amend the drug establishment registration and drug listing requirements with respect to establishments engaged in distributed manufacturing and foreign drug establishments. This action, if finalized, will provide a pathway for a distributed manufacturing establishment that manufactures drugs at multiple different physical locations to register as a single drug manufacturing establishment and align drug establishment registration and drug listing regulations applicable to foreign drug establishments with statutory changes made by the Preparing for and Responding to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act).","document_number":"2026-14073","html_url":"https://www.federalregister.gov/documents/2026/07/13/2026-14073/drug-establishment-registration-and-drug-listing-requirements-for-establishments-engaged-in","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-13/pdf/2026-14073.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-14073.pdf?1783687517","publication_date":"2026-07-13","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"271), and section 2511(b) of the PREVENT Pandemics Act. \n D. Costs and Benefits \n \n We quantify costs to drug manufacturers for reading and understanding the rule and to FDA for updating structured product labeling (SPL) submission schema, tools, and internal databases. Using a pre-statute baseline, we also estimate costs to unregistered foreign firms required to register and list with FDA, as we expect clarifying changes to statute made by section 2511 of the PREVENT Pandemics Act to increase compliance among covered foreign establishments. At"},{"title":"Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products; Draft Guidance for Industry; Availability","type":"Notice","abstract":"The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Oncology Pharmaceuticals: Streamlined Nonclinical Safety Studies for Biologics and Conjugated Products.\" When finalized, this guidance will assist sponsors in implementing streamlined approaches for general toxicology, for nonclinical safety assessments of certain oncology pharmaceuticals. The guidance is intended to facilitate drug development for biological products and conjugated products for the treatment of cancer while avoiding unnecessary animal use. The recommendations in this draft guidance are informed by data analysis of general toxicology studies and practices developed during the COVID-19 pandemic to reduce use of non-human primates.","document_number":"2026-10873","html_url":"https://www.federalregister.gov/documents/2026/06/01/2026-10873/oncology-pharmaceuticals-streamlined-nonclinical-safety-studies-for-biologics-and-conjugated","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-01/pdf/2026-10873.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10873.pdf?1780058723","publication_date":"2026-06-01","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"development for biological products and conjugated products for the treatment of cancer while avoiding unnecessary animal use. The recommendations in this draft guidance are informed by data analysis of general toxicology studies and practices developed during the COVID-19 pandemic to reduce use of non-human primates. \n \n \n DATES: \n Submit either electronic or written comments on the draft guidance by July 31, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. \n "},{"title":"Agency Information Collection Activities; Submission for OMB Review; Comment Request; Proposed New Information Collection; Survey of the Costs of AML/CFT Compliance","type":"Notice","abstract":"The Department of the Treasury (Treasury) will submit the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995 (PRA), on or after the date of publication of this notice. The public is invited to submit comments on this request.","document_number":"2026-08242","html_url":"https://www.federalregister.gov/documents/2026/04/28/2026-08242/agency-information-collection-activities-submission-for-omb-review-comment-request-proposed-new","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-28/pdf/2026-08242.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08242.pdf?1777293915","publication_date":"2026-04-28","agencies":[{"raw_name":"DEPARTMENT OF THE TREASURY","name":"Treasury Department","id":497,"url":"https://www.federalregister.gov/agencies/treasury-department","json_url":"https://www.federalregister.gov/api/v1/agencies/497","parent_id":null,"slug":"treasury-department"}],"excerpts":"Financial Crimes Enforcement Network (FinCEN) \n \n Title: \n Survey of the Costs of AML/CFT Compliance.\n \n \n OMB Control Number: \n 1506-NEW.\n \n \n Type of Request: \n New Collection.\n \n \n Description: \n This information collection will seek information on anti-money laundering/countering the financing of terrorism (AML/CFT) compliance costs and related topics via a survey. The survey is voluntary. The purpose of the survey is to better understand the cost of AML/CFT compliance by financial institutions \n 1 \n \n subject to the Bank Secrecy Act (BSA) and applicable"},{"title":"Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications; Guidance for Industry; Availability","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled \"Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications.\" This guidance provides information to applicants on how FDA intends to use alternative tools to assess drug manufacturing facilities identified in a marketing application (i.e., a new drug application (NDA), an abbreviated new drug application (ANDA), a biologics license application (BLA), or a supplement to any of these types of applications). As part of the negotiations relating to the reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilar User Fee Act (BsUFA), as described in \"PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2023 Through 2027\" (PDUFA VII commitment letter) and \"Biosimilar Biological Product Reauthorization Performance Goals and Procedures for Fiscal Years 2023 Through 2027\" (BsUFA III commitment letter), FDA agreed to issue guidance on the use of alternative tools to assess manufacturing facilities named in pending applications and to incorporate best practices from the use of such tools during the Coronavirus Disease 2019 (COVID-19) pandemic. This guidance finalizes the draft guidance of the same title issued on September 22, 2023.","document_number":"2025-17698","html_url":"https://www.federalregister.gov/documents/2025/09/12/2025-17698/alternative-tools-assessing-drug-manufacturing-facilities-identified-in-pending-applications","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-09-12/pdf/2025-17698.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-17698.pdf?1757594721","publication_date":"2025-09-12","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"relating to the submission of BLAs have been approved under OMB control number 0910-0338. \n III. Electronic Access \n \n Persons with access to the internet may obtain the guidance at\n https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances, https:/www.fda.gov/regulatory-information/search-fda-guidance-documents, \n or \n https://www.regulations.gov. \n \n \n Grace R. Graham, \n Deputy Commissioner for Policy"},{"title":"TRICARE Coverage of Clinical Trials and Termination of Expanded Access Treatments","type":"Rule","abstract":"The Assistant Secretary of Defense for Health Affairs (ASD(HA)) issues this final rule regarding circumstances under which services and supplies related to emerging treatments may be covered under the TRICARE program. This rule finalizes provisions published in two interim final rules (IFRs) with request for comment, which temporarily added coverage for the treatment use of investigational drugs under U.S. Food and Drug Administration (FDA)-authorized expanded access (EA) programs when for the treatment of coronavirus disease 2019 (COVID-19) and permitted coverage of National Institute of Allergy and Infectious Disease (NIAID)-sponsored clinical trials for the treatment or prevention of COVID-19. This final rule discusses the DoD's decision not to make permanent the coverage of treatment use of investigational drugs under FDA EA programs while updating language for care associated with their administration and broadens the COVID-19 clinical trial benefit to include coverage of clinical trials sponsored or approved by any National Institutes of Health (NIH) Center or Institute to treat or prevent infectious diseases associated with a pandemic or epidemic. Lastly, the final rule expands TRICARE's clinical trial benefit by covering services and supplies provided in conjunction with Phase I, II, III, and IV clinical trials that are NIH-sponsored or approved and that involve a new treatment or cure for a specific condition or the treatment of a currently uncontrolled symptom or aspect of that condition, provided that the condition is severely debilitating, life- threatening, or a rare disease.","document_number":"2025-14206","html_url":"https://www.federalregister.gov/documents/2025/07/28/2025-14206/tricare-coverage-of-clinical-trials-and-termination-of-expanded-access-treatments","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-07-28/pdf/2025-14206.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-14206.pdf?1753447522","publication_date":"2025-07-28","agencies":[{"raw_name":"DEPARTMENT OF DEFENSE","name":"Defense Department","id":103,"url":"https://www.federalregister.gov/agencies/defense-department","json_url":"https://www.federalregister.gov/api/v1/agencies/103","parent_id":null,"slug":"defense-department"},{"raw_name":"Office of the Secretary"}],"excerpts":"(85 FR 27921-27927), titled “TRICARE Coverage and Payment for Certain Services in Response to the COVID-19 Pandemic,” were finalized in a final rule, titled “TRICARE Coverage and Reimbursement of Certain Services Resulting From Temporary Program Changes in Response to the COVID-19 Pandemic,” published on June 1, 2022 (87 FR 33001-33015). The DoD published a fourth IFR titled “Expanding TRICARE Access to Care in Response to the COVID-19 Pandemic” on January 12, 2023 (88 FR 1992-2002); its provisions have not yet been finalized in a final rule. \n In"},{"title":"Homeland Security Acquisition Regulation, Make Personal Protective Equipment in America Act Restrictions on Foreign Acquisition (HSAR Case 2024-003)","type":"Proposed Rule","abstract":"DHS is proposing to amend the Homeland Security Acquisition Regulation (HSAR) to add a new subpart, clause, and provision that would codify how DHS complies with the requirements of the Make Personal Protective Equipment (PPE) in America Act. DHS believes these proposed changes would help to ensure the sustainment and expansion of domestic manufacturing for certain types of PPE critical to the United States' national response to a public health crisis, such as the COVID- 19 pandemic.","document_number":"2024-22303","html_url":"https://www.federalregister.gov/documents/2024/10/01/2024-22303/homeland-security-acquisition-regulation-make-personal-protective-equipment-in-america-act","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-10-01/pdf/2024-22303.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-22303.pdf?1727700323","publication_date":"2024-10-01","agencies":[{"raw_name":"DEPARTMENT OF HOMELAND SECURITY","name":"Homeland Security Department","id":227,"url":"https://www.federalregister.gov/agencies/homeland-security-department","json_url":"https://www.federalregister.gov/api/v1/agencies/227","parent_id":null,"slug":"homeland-security-department"}],"excerpts":"not reviewed this regulatory action. \n Background \n \n During the COVID-19 pandemic, the United States encountered challenges obtaining PPE in adequate amounts to address the urgent public health and safety need. This was in part due to an unprecedented increase in demand for PPE and challenges in the supply chain. Before the COVID-19 pandemic, domestic production of PPE was limited and most PPE used in the United States was predominantly imported.\n 20 \n \n The COVID-19 pandemic exposed the vulnerability of the United States PPE supply chains and lack"},{"title":"Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; COVID-19 Provider Relief Fund and American Rescue Plan Rural Payment Reporting Activities, OMB No. 0906-0068-Revision","type":"Notice","abstract":"In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.","document_number":"2026-00088","html_url":"https://www.federalregister.gov/documents/2026/01/07/2026-00088/agency-information-collection-activities-submission-to-omb-for-review-and-approval-public-comment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-01-07/pdf/2026-00088.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-00088.pdf?1767707112","publication_date":"2026-01-07","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Health Resources and Services Administration","name":"Health Resources and Services Administration","id":222,"url":"https://www.federalregister.gov/agencies/health-resources-and-services-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/222","parent_id":221,"slug":"health-resources-and-services-administration"}],"excerpts":"lost revenues attributable to the COVID-19 pandemic. Recipients of PRF and ARP Rural payments agreed to a set of Terms and Conditions (T&C), which, among other requirements, mandate compliance with certain reporting requirements that facilitate appropriate oversight of recipients' use of funds. Providers who have attested to the T&Cs regarding their PRF and ARP Rural payment(s), including the requirement that the provider “shall submit reports as the Secretary determines are needed to ensure compliance with conditions that are imposed on this"},{"title":"TRICARE; Removal of Certain Temporary Regulation Changes Made in Response to COVID-19","type":"Rule","abstract":"The ASD(HA) is issuing this direct final rule to remove certain temporary regulation changes put in place in response to the coronavirus disease 2019 (COVID-19) pandemic that were automatically terminated by the end of the President's national emergency and the associated Health and Human Services (HHS) Public Health Emergency (PHE). This rule is being published as a direct final rule as the Department does not expect to receive any adverse comments. If such comments are received, and are significant, this direct final rule will be withdrawn and a proposed rule for comments will be published.","document_number":"2024-11219","html_url":"https://www.federalregister.gov/documents/2024/05/24/2024-11219/tricare-removal-of-certain-temporary-regulation-changes-made-in-response-to-covid-19","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-05-24/pdf/2024-11219.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-11219.pdf?1716468315","publication_date":"2024-05-24","agencies":[{"raw_name":"DEPARTMENT OF DEFENSE","name":"Defense Department","id":103,"url":"https://www.federalregister.gov/agencies/defense-department","json_url":"https://www.federalregister.gov/api/v1/agencies/103","parent_id":null,"slug":"defense-department"},{"raw_name":"Office of the Secretary"}],"excerpts":"ACTION: \n Direct final rule. \n \n \n SUMMARY: \n The ASD(HA) is issuing this direct final rule to remove certain temporary regulation changes put in place in response to the coronavirus disease 2019 (COVID-19) pandemic that were automatically terminated by the end of the President's national emergency and the associated Health and Human Services (HHS) Public Health Emergency (PHE). This rule is being published as a direct final rule as the Department does not expect to receive any adverse comments. If such comments are received, and are significant"},{"title":"Economic Growth Regulatory Relief and Consumer Protection Act: Implementation of National Standards for the Physical Inspection of Real Estate (NSPIRE); Extension of NSPIRE Compliance Date for HCV, PBV and Section 8 Moderate Rehab and CPD Programs","type":"Notice","abstract":"This notice further extends the compliance date for HUD's National Standards for the Physical Inspection of Real Estate (NSPIRE) final rule for the Housing Choice Voucher (HCV), Project Based Voucher (PBV) and Section 8 Moderate Rehabilitation programs, and for the HOME Investment Partnerships Program (HOME) and Housing Trust Fund (HTF), Housing Opportunities for Persons With AIDS (HOPWA), Emergency Solution Grants (ESG) and Continuum of Care (COC) programs (\"CPD programs\"), until October 1, 2025. HUD is taking this action to allow Public Housing Authorities (PHAs), jurisdictions, participants, recipients, and grantees additional time to implement HUD's NSPIRE standards. This is the second extension of this compliance date.","document_number":"2024-14718","html_url":"https://www.federalregister.gov/documents/2024/07/05/2024-14718/economic-growth-regulatory-relief-and-consumer-protection-act-implementation-of-national-standards","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14718.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-14718.pdf?1720010722","publication_date":"2024-07-05","agencies":[{"raw_name":"DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT","name":"Housing and Urban Development Department","id":228,"url":"https://www.federalregister.gov/agencies/housing-and-urban-development-department","json_url":"https://www.federalregister.gov/api/v1/agencies/228","parent_id":null,"slug":"housing-and-urban-development-department"}],"excerpts":"NSPIRE and established an effective date for these amendments of October 1, 2023. In September 2023, HUD delayed the compliance date for CPD programs (88 FR 63971) and for the HCV and PBV programs (88 FR 66882) until October 1, 2024, to allow PHAs, jurisdictions, participants, recipients, and HUD grantees additional time for implementation. \n II. Basis for Delay of Compliance Date \n Through this notice, HUD further delays the compliance date for CPD programs and for the HCV and PBV programs until October 1, 2025. HUD encourages any PHA, participating"},{"title":"Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: COVID-19 Provider Relief Fund (PRF) and American Rescue Plan (ARP) Rural Payment Reporting Activities, OMB No. 0906-0068-Revision","type":"Notice","abstract":"In compliance with the requirement for opportunity for public comment on proposed data collection projects of the Paperwork Reduction Act of 1995, HRSA announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.","document_number":"2025-11746","html_url":"https://www.federalregister.gov/documents/2025/06/26/2025-11746/agency-information-collection-activities-proposed-collection-public-comment-request-information","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-06-26/pdf/2025-11746.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-11746.pdf?1750855511","publication_date":"2025-06-26","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Health Resources and Services Administration","name":"Health Resources and Services Administration","id":222,"url":"https://www.federalregister.gov/agencies/health-resources-and-services-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/222","parent_id":221,"slug":"health-resources-and-services-administration"}],"excerpts":"revenues attributable to the COVID-19 pandemic. Recipients of PRF and ARP Rural payments agreed to a set of Terms & Conditions (T&Cs), which, among other requirements, mandate compliance with certain reporting requirements that facilitate appropriate oversight of recipients' use of funds. Providers who have attested to the T&Cs regarding their PRF and ARP Rural payment(s), including the requirement that the provider “shall submit reports as the Secretary determines are needed to ensure compliance with conditions that are imposed on this"},{"title":"Small Business Lending Under the Equal Credit Opportunity Act (Regulation B); Extension of Compliance Dates","type":"Rule","abstract":"In light of court orders in ongoing litigation, the Consumer Financial Protection Bureau (CFPB or Bureau) is amending Regulation B to extend the compliance dates set forth in its 2023 small business lending rule and to make other date-related conforming adjustments.","document_number":"2024-14396","html_url":"https://www.federalregister.gov/documents/2024/07/03/2024-14396/small-business-lending-under-the-equal-credit-opportunity-act-regulation-b-extension-of-compliance","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-07-03/pdf/2024-14396.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-14396.pdf?1719924315","publication_date":"2024-07-03","agencies":[{"raw_name":"Consumer Financial Protection Bureau","name":"Consumer Financial Protection Bureau","id":573,"url":"https://www.federalregister.gov/agencies/consumer-financial-protection-bureau","json_url":"https://www.federalregister.gov/api/v1/agencies/573","parent_id":null,"slug":"consumer-financial-protection-bureau"}],"excerpts":"this interim final rule, the CFPB is extending the compliance dates set forth in the 2023 final rule and making conforming adjustments. Consistent with existing court orders, the compliance dates are being extended 290 days to compensate for the period the rule was stayed (July 31, 2023 to May 16, 2024). Thus, covered financial institutions must begin collecting data as follows:\n \n \n \n Table 1—Compliance Dates and Filing Deadlines \n \n Compliance tier \n \n Original\n compliance date \n \n New compliance date \n First filing deadline \n \n \n Highest volume"},{"title":"Agency Information Collection Activity Under OMB Review: Transit COVID-19 Response Program","type":"Notice","abstract":"In compliance with the Paperwork Reduction Act of 1995, this notice announces that the Information Collection Requirements (ICRs) abstracted below have been forwarded to the Office of Management and Budget (OMB) for review and comment. The ICR describe the nature of the information collection and their expected burdens.","document_number":"2024-31194","html_url":"https://www.federalregister.gov/documents/2024/12/30/2024-31194/agency-information-collection-activity-under-omb-review-transit-covid-19-response-program","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-12-30/pdf/2024-31194.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-31194.pdf?1735307153","publication_date":"2024-12-30","agencies":[{"raw_name":"DEPARTMENT OF TRANSPORTATION","name":"Transportation Department","id":492,"url":"https://www.federalregister.gov/agencies/transportation-department","json_url":"https://www.federalregister.gov/api/v1/agencies/492","parent_id":null,"slug":"transportation-department"},{"raw_name":"Federal Transit Administration","name":"Federal Transit Administration","id":193,"url":"https://www.federalregister.gov/agencies/federal-transit-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/193","parent_id":492,"slug":"federal-transit-administration"}],"excerpts":"ACTION: \n Notice of request for comments. \n \n \n SUMMARY: \n In compliance with the Paperwork Reduction Act of 1995, this notice announces that the Information Collection Requirements (ICRs) abstracted below have been forwarded to the Office of Management and Budget (OMB) for review and comment. The ICR describe the nature of the information collection and their expected burdens. \n \n \n DATES: \n Comments must be submitted on or before January 29, 2025. \n \n \n ADDRESSES: \n \n Written comments and recommendations for the proposed information collection"},{"title":"Platform Technology Designation Program; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request","type":"Notice","abstract":"The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled \"Platform Technology Designation Program for Drug Development.\" The purpose of this draft guidance is to provide details about the implementation of the Platform Technology Designation Program established by the PREVENT Pandemics Act. This draft guidance outlines eligibility factors for receiving a platform technology designation, potential benefits of receiving a designation, how to leverage data from designated platform technologies, how to discuss the planned designation request as part of a milestone meeting, the recommended content of a designation request submission, and the review timelines for a designation request. This draft guidance, when finalized, will represent the current thinking of FDA.","document_number":"2024-11686","html_url":"https://www.federalregister.gov/documents/2024/05/29/2024-11686/platform-technology-designation-program-draft-guidance-for-industry-availability-agency-information","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-05-29/pdf/2024-11686.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-11686.pdf?1716900318","publication_date":"2024-05-29","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"availability of a draft guidance for industry entitled “Platform Technology Designation Program for Drug Development.” The purpose of this draft guidance is to provide details about the implementation of the Platform Technology Designation Program established by the PREVENT Pandemics Act. This draft guidance outlines eligibility factors for receiving a platform technology designation, potential benefits of receiving a designation, how to leverage data from designated platform technologies, how to discuss the planned designation request as part of a milestone"},{"title":"Agency Information Collection Activity Under OMB Review: Industry Standard Forms for Completing an Appraisal Required by VA","type":"Notice","abstract":"In compliance with the Paperwork Reduction Act (PRA) of 1995, this notice announces that the Veterans Benefits Administration, Department of Veterans Affairs, will submit the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden and it includes the actual data collection instrument.","document_number":"2024-26803","html_url":"https://www.federalregister.gov/documents/2024/11/18/2024-26803/agency-information-collection-activity-under-omb-review-industry-standard-forms-for-completing-an","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-11-18/pdf/2024-26803.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-26803.pdf?1731678338","publication_date":"2024-11-18","agencies":[{"raw_name":"DEPARTMENT OF VETERANS AFFAIRS","name":"Veterans Affairs Department","id":520,"url":"https://www.federalregister.gov/agencies/veterans-affairs-department","json_url":"https://www.federalregister.gov/api/v1/agencies/520","parent_id":null,"slug":"veterans-affairs-department"}],"excerpts":"ACTION: \n Notice. \n \n \n SUMMARY: \n In compliance with the Paperwork Reduction Act (PRA) of 1995, this notice announces that the Veterans Benefits Administration, Department of Veterans Affairs, will submit the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden and it includes the actual data collection instrument. \n \n \n DATES: \n Comments and recommendations for the proposed information"},{"title":"Modifications to Performance Standards During Natural Disasters and Other Calamities","type":"Rule","abstract":"OCSS issues this final rule to provide temporary relief to states from certain child support program performance requirements and penalties during natural disasters and other calamities which have a negative impact on state child support program operations. The rule allows OCSS to modify performance measure requirements when natural disasters and other calamities affect, or are expected to affect, the state child support program's ability to achieve performance standards for paternity establishment, support order establishment, and current collections. The rule enables states to avoid the imposition of penalties due to adverse data reliability audit findings during, and after, natural disasters and other calamities, including pandemics and declared public health emergencies.","document_number":"2024-04244","html_url":"https://www.federalregister.gov/documents/2024/03/04/2024-04244/modifications-to-performance-standards-during-natural-disasters-and-other-calamities","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04244.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-04244.pdf?1709300721","publication_date":"2024-03-04","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Administration for Children and Families","name":"Children and Families Administration","id":49,"url":"https://www.federalregister.gov/agencies/children-and-families-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/49","parent_id":221,"slug":"children-and-families-administration"}],"excerpts":"the COVID-19 pandemic. During the COVID-19 pandemic, states experienced significant workload burdens and service backlogs due to disruptions to state child support program operations and court closures. \n \n State child support program operations were affected in a variety of ways, including being unable to obtain voluntary acknowledgments through in-hospital programs or to access genetic testing due to child support office closures, court closures, staffing shortages, or when clinical laboratory resources were diverted for pandemic-related testing"},{"title":"Control of Communicable Diseases; Foreign Quarantine","type":"Rule","abstract":"The Centers for Disease Control and Prevention (CDC) within the U.S. Department of Health and Human Services (HHS) issues this interim final rule with request for comments to amend its Foreign Quarantine Regulations. This interim final rule provides a procedure for the Secretary acting through the CDC Director or other delegate to suspend the introduction of persons from designated countries or places, if required, in the interest of public health.","document_number":"2026-10543","html_url":"https://www.federalregister.gov/documents/2026/05/27/2026-10543/control-of-communicable-diseases-foreign-quarantine","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-27/pdf/2026-10543.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10543.pdf?1779480907","publication_date":"2026-05-27","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"individuals may have little or no immunity, which can lead to a pandemic when the virus passes easily from human to human and causes serious illness or death. The most recent influenza pandemics include H1N1 in 2009-2010, the 1968-1969 Hong Kong Flu, the 1957-1958 Asian Flu, and the 1918-1919 Spanish Flu. \n It is difficult to predict the impact that another emerging, or re-emerging, quarantinable communicable disease would have on the U.S. public health system. The 2009 H1N1 pandemic caused between 100,000 and 600,000 deaths worldwide, while the"},{"title":"Rescission of the National Transit Database Weekly Reference Reporting Requirement","type":"Notice","abstract":"This notice finalizes and responds to comments on the proposed rescission of the National Transit Database's (NTD) Weekly Reference (WE-20) reporting requirement.","document_number":"2026-00651","html_url":"https://www.federalregister.gov/documents/2026/01/15/2026-00651/rescission-of-the-national-transit-database-weekly-reference-reporting-requirement","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-01-15/pdf/2026-00651.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-00651.pdf?1768398310","publication_date":"2026-01-15","agencies":[{"raw_name":"DEPARTMENT OF TRANSPORTATION","name":"Transportation Department","id":492,"url":"https://www.federalregister.gov/agencies/transportation-department","json_url":"https://www.federalregister.gov/api/v1/agencies/492","parent_id":null,"slug":"transportation-department"},{"raw_name":"Federal Transit Administration","name":"Federal Transit Administration","id":193,"url":"https://www.federalregister.gov/agencies/federal-transit-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/193","parent_id":492,"slug":"federal-transit-administration"}],"excerpts":"Budget and Policy, 202-366-4000, \n chelsea.champlin@dot.gov. \n \n \n \n \n SUPPLEMENTARY INFORMATION: \n I. Background \n Congress established the NTD to be the Nation's primary source for information and statistics on the transit systems of the United States. During the COVID-19 pandemic, FTA found it did not have sufficient and timely data on transit ridership or transit service levels to inform decision-makers during the rapidly changing crisis situation. To better understand changes in the transit industry on a timely basis, FTA went through the notice"},{"title":"Lifeline and Link Up Reform and Modernization; Bridging the Digital Divide for Low-Income Consumers; Telecommunications Carriers Eligible for Universal Service Support; Affordable Connectivity Program; Emergency Broadband Benefit Program","type":"Proposed Rule","abstract":"In this document, the Federal Communications Commission (Commission) seeks to ensure that Lifeline services are used to benefit and support eligible low-income Americans, that the program's funding is protected from waste, fraud, and abuse, and that service providers are in compliance with Commission rules. The Commission also seeks to update and streamline Lifeline and related rules.","document_number":"2026-06531","html_url":"https://www.federalregister.gov/documents/2026/04/03/2026-06531/lifeline-and-link-up-reform-and-modernization-bridging-the-digital-divide-for-low-income-consumers","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-03/pdf/2026-06531.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-06531.pdf?1775133915","publication_date":"2026-04-03","agencies":[{"raw_name":"FEDERAL COMMUNICATIONS COMMISSION","name":"Federal Communications Commission","id":161,"url":"https://www.federalregister.gov/agencies/federal-communications-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/161","parent_id":null,"slug":"federal-communications-commission"}],"excerpts":"attached to compliance plans, once approved, that would result in automatic termination of the compliance plan if the condition is violated? The Commission seeks comments on what the conditions should be for terminating a Lifeline compliance plan. Should Lifeline compliance plans terminate when ETCs are found guilty of committing fraud or other misconduct in the Lifeline program? Should compliance plans terminate when ETCs change corporate ownership or control without notifying the Commission and receiving approval of an updated compliance plan? Or"},{"title":"Rescinding Portions of DHS Title VI Regulations To Conform More Closely With the Statutory Text and To Implement Executive Order 14281","type":"Rule","abstract":"By this rule, DHS amends its regulations implementing Title VI of the Civil Rights Act of 1964 (Title VI) consistent with a recent rule issued by the Department of Justice (DOJ). Like the DOJ rule, this rule aligns the DHS regulations more closely with Title VI's original public meaning, avoids constitutional concerns, reduces compliance costs, and serves the public interest.","document_number":"2026-12399","html_url":"https://www.federalregister.gov/documents/2026/06/22/2026-12399/rescinding-portions-of-dhs-title-vi-regulations-to-conform-more-closely-with-the-statutory-text-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-22/pdf/2026-12399.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12399.pdf?1781786715","publication_date":"2026-06-22","agencies":[{"raw_name":"DEPARTMENT OF HOMELAND SECURITY","name":"Homeland Security Department","id":227,"url":"https://www.federalregister.gov/agencies/homeland-security-department","json_url":"https://www.federalregister.gov/api/v1/agencies/227","parent_id":null,"slug":"homeland-security-department"},{"raw_name":"Office of the Secretary"},{"raw_name":"FEDERAL EMERGENCY MANAGEMENT AGENCY","name":"Federal Emergency Management Agency","id":166,"url":"https://www.federalregister.gov/agencies/federal-emergency-management-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/166","parent_id":227,"slug":"federal-emergency-management-agency"}],"excerpts":"changes. But the deregulatory action should result in greater flexibility and lower compliance costs. DHS recognizes that a funding recipient may receive additional federal funds from sources other than DHS. DOJ noted in its rule that DOJ expected its rule to cause other federal departments and agencies to consider similarly revising their Title VI regulations. Like DOJ, DHS does not envision that this rule will appreciably increase administrative costs or compliance costs for funding recipients who must also adhere to the regulations of another department"},{"title":"Uniform Allowances","type":"Rule","abstract":"The Office of Personnel Management (OPM) is issuing a direct final rule to raise the maximum annual uniform allowance and the maximum allowable cost payable by the agency for furnishing uniforms from $800 to $1,500, amend the purpose of the subpart and the definition of \"uniform,\" and ensure agencies maintain policies for administering uniform allowance programs. This document also provides guidance on appropriate and inappropriate uses of the allowance, distinguishes uniforms from personal protective equipment, and makes technical edits to improve transparency, accountability, and usability.","document_number":"2026-07245","html_url":"https://www.federalregister.gov/documents/2026/04/14/2026-07245/uniform-allowances","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-14/pdf/2026-07245.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-07245.pdf?1776084325","publication_date":"2026-04-14","agencies":[{"raw_name":"OFFICE OF PERSONNEL MANAGEMENT","name":"Personnel Management Office","id":406,"url":"https://www.federalregister.gov/agencies/personnel-management-office","json_url":"https://www.federalregister.gov/api/v1/agencies/406","parent_id":null,"slug":"personnel-management-office"}],"excerpts":"Inflation During the COVID-19 Pandemic,” Federal Reserve Bank of St. Louis \n Review, \n Second Quarter 2022, pp. 78-91. Available at: \n https://www.stlouisfed.org/publications/review/2022/02/07/global-supply-chain-disruptions-and-inflation-during-the-covid-19-pandemic \n (Accessed February 24, 2026).\n \n \n • National Bureau of Economic Research. (2024). “Supply Chain Disruptions and Pandemic-Era Inflation.” \n NBER Digest, \n April 2024. Available at: \n https://www.nber.org/digest/202404/supply-chain-disruptions-and-pandemic-era-inflation \n (Accessed February"}]}